Casdin Capital
Latest statistics and disclosures from Casdin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are WGS, BLFS, RVMD, LAB, RNA, and represent 66.46% of Casdin Capital's stock portfolio.
- Added to shares of these 10 stocks: TEM (+$24M), SPRY (+$16M), GPCR (+$9.2M), PRME (+$8.9M), UNH (+$8.6M), INCY (+$8.5M), BEAM, Bridgebio Oncology Therapeut, LAB, RNA.
- Started 5 new stock positions in INCY, Bridgebio Oncology Therapeut, SPRY, TEM, UNH.
- Reduced shares in these 10 stocks: WGS (-$54M), VERV (-$46M), BLFS (-$26M), CDXS (-$18M), SRPT (-$17M), ALNY (-$12M), ILMN (-$11M), RVMD (-$11M), LLY (-$6.6M), SNDX (-$6.1M).
- Sold out of its positions in AGIO, CDXS, LLY, SRPT, SNDX, VERV.
- Casdin Capital was a net seller of stock by $-127M.
- Casdin Capital has $1.2B in assets under management (AUM), dropping by 9.21%.
- Central Index Key (CIK): 0001534261
Tip: Access up to 7 years of quarterly data
Positions held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Casdin Capital
Casdin Capital holds 32 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Genedx Holdings Corp Com Cl A (WGS) | 27.0 | $324M | -14% | 3.0M | 107.74 |
|
| Biolife Solutions Com New (BLFS) | 14.3 | $171M | -12% | 6.7M | 25.51 |
|
| Revolution Medicines (RVMD) | 10.3 | $124M | -8% | 2.6M | 46.70 |
|
| D Fluidigm Corp Del (LAB) | 8.4 | $101M | 78M | 1.30 |
|
|
| Avidity Biosciences Ord (RNA) | 6.5 | $78M | 1.8M | 43.57 |
|
|
| Relay Therapeutics (RLAY) | 4.9 | $59M | 11M | 5.22 |
|
|
| Illumina (ILMN) | 4.2 | $50M | -18% | 525k | 94.97 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.6 | $44M | +26% | 1.6M | 28.00 |
|
| Beam Therapeutics (BEAM) | 3.2 | $39M | +10% | 1.6M | 24.27 |
|
| Alnylam Pharmaceuticals (ALNY) | 2.1 | $25M | -32% | 55k | 456.00 |
|
| Tempus Ai Cl A (TEM) | 2.0 | $24M | NEW | 294k | 80.71 |
|
| Neurogene (NGNE) | 1.9 | $22M | 1.3M | 17.33 |
|
|
| Maze Therapeatics (MAZE) | 1.6 | $20M | 759k | 25.93 |
|
|
| Prime Medicine (PRME) | 1.5 | $18M | +102% | 3.2M | 5.54 |
|
| Silverback Therapeutics (SPRY) | 1.3 | $16M | NEW | 1.6M | 10.05 |
|
| Hims & Hers Health Com Cl A (HIMS) | 1.1 | $13M | 230k | 56.72 |
|
|
| Denali Therapeutics (DNLI) | 1.1 | $13M | 890k | 14.52 |
|
|
| Septerna (SEPN) | 0.9 | $10M | 553k | 18.81 |
|
|
| Veracyte (VCYT) | 0.8 | $9.5M | 276k | 34.33 |
|
|
| UnitedHealth (UNH) | 0.7 | $8.6M | NEW | 25k | 345.30 |
|
| Incyte Corporation (INCY) | 0.7 | $8.5M | NEW | 100k | 84.81 |
|
| Guardant Health (GH) | 0.5 | $6.2M | 100k | 62.48 |
|
|
| EXACT Sciences Corporation (EXAS) | 0.4 | $4.9M | 90k | 54.71 |
|
|
| Bridgebio Oncology Therapeut Com New | 0.3 | $3.3M | NEW | 282k | 11.58 |
|
| Absci Corp (ABSI) | 0.2 | $3.0M | 973k | 3.04 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $1.7M | 148k | 11.75 |
|
|
| Pacific Biosciences of California (PACB) | 0.1 | $926k | 724k | 1.28 |
|
|
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.1 | $807k | 165k | 4.88 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.1 | $637k | 86k | 7.41 |
|
|
| Century Therapeutics (IPSC) | 0.1 | $612k | 1.2M | 0.50 |
|
|
| Tenaya Therapeutics (TNYA) | 0.0 | $586k | 362k | 1.62 |
|
|
| Ginkgo Bioworks Holdings Cl A New (DNA) | 0.0 | $532k | 37k | 14.58 |
|
Past Filings by Casdin Capital
SEC 13F filings are viewable for Casdin Capital going back to 2015
- Casdin Capital 2025 Q3 filed Nov. 14, 2025
- Casdin Capital 2025 Q2 filed Aug. 14, 2025
- Casdin Capital 2025 Q1 filed May 15, 2025
- Casdin Capital 2024 Q4 filed Feb. 14, 2025
- Casdin Capital 2024 Q3 filed Nov. 14, 2024
- Casdin Capital 2024 Q2 restated filed Oct. 18, 2024
- Casdin Capital 2024 Q2 filed Aug. 14, 2024
- Casdin Capital 2024 Q1 filed May 15, 2024
- Casdin Capital 2023 Q4 filed Feb. 14, 2024
- Casdin Capital 2023 Q3 filed Nov. 14, 2023
- Casdin Capital 2023 Q2 filed Aug. 14, 2023
- Casdin Capital 2023 Q1 filed May 15, 2023
- Casdin Capital 2022 Q4 filed Feb. 14, 2023
- Casdin Capital 2022 Q3 filed Nov. 14, 2022
- Casdin Capital 2022 Q2 filed Aug. 15, 2022
- Casdin Capital 2022 Q1 filed May 16, 2022